ATTACHMENT, TARGETING & LOCALIZATION OF G ALPHA SUBUNIT
Project Number5R29GM055223-03
Contact PI/Project LeaderDENKER, BRADLEY M
Awardee OrganizationBRIGHAM AND WOMEN'S HOSPITAL
Description
Abstract Text
DESCRIPTION (Adapted from applicant's abstract): Heterotrimeric guanine
nucleotide binding proteins (G proteins), composed of Galpha and Gbeta/gamma
subunits, transduce signals across cell membranes from receptors to a
variety of effectors that include adenylyl cyclases, phosphodiesterases,
phospholipases and ion channels. Receptor-stimulation causes Galpha to
exchange GTP for GDP and dissociation from Gbeta/gamma. Both subunits
interact with effectors until Galpha hydrolyzes GTP to GDP.
Hormone-receptor interactions are very specific, but many receptor-G protein
interactions are less specific. Reconstitution studies with G proteins,
receptors and effectors show that many Galpha subunits can couple to the
same receptor and effector. Since multiple G-protein-coupled signaling
pathways exist in every eukaryotic cell, there is the potential for
crosstalk between signaling pathways. A proposal is that localizing G
proteins in specific membrane domains is an important mechanism for signal
specificity. This proposal will use mutant Galpha subunits (some already
characterized and new one to be made based on crystal structures) to address
questions of how Galpha attaches to the membrane, and localizes in specific
membrane domains. The interactions of Galpha subunits with the membrane
vary among Galpha families. Using in vitro assays and transient
transfections, mutations at both the N- and C-termini of Galpha-o, Galpha-s
and Galpha-q will be used to identify regions important to membrane binding
that are in addition to known roles from lipids and interactions with
beta/gamma. With these techniques, amino acids 11-14 of Galpha-o have been
found to contribute to membrane binding through an unidentified membrane
protein(s). The targeting of Galpha to specific membrane domains is being
studied in MDCK cells (polarized epithelia). To follow Galpha in these
cells, stable cell lines expressing Galpha-o (not normally expressed) and
epitope tagged Galpha subunits are being established and characterized by
immunofluorescence and confocal microscopy. Galpha-o localizes to the
lateral membrane and overlaps with the endogenous Galpha-i2 and ZO-1 (tight
junction (TJ) protein). Mutant Galpha-o subunits and chimeras of Galpha-o
and Galpha-s (both apical and basolateral localization) will be used to
identify regions important for specific membrane targeting. The pathway(s)
of targeting will be established for Galpha-o and endogenous Galpha i2,
Galpha-s, and Galpha-q by pulse chase labeling and selective membrane
biotinylation. Expression of activated Galpha-o (Q205L) also localizes to
the basolateral membrane and causes accelerated formation of TJs using the
Ca+2 switch model of TJ biogenesis. A role for Galpha subunits in TJ
biogenesis will be further characterized with stable cell lines expressing
wildtype and activated Galpha subunits. Accurate signaling is critical for
all cells, and signaling pathways are often disrupted after ischemic tissue
injury. TJ formation is critical in developing epithelial tissues and
during recovery from ischemia (acute tubular necrosis). These studies may
give new insights to an understanding of signal specificity in all cells,
and may permit the development of strategies to prevent or correct aberrant
signaling in diseased or injured tissues.
No Sub Projects information available for 5R29GM055223-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R29GM055223-03
Patents
No Patents information available for 5R29GM055223-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R29GM055223-03
Clinical Studies
No Clinical Studies information available for 5R29GM055223-03
News and More
Related News Releases
No news release information available for 5R29GM055223-03
History
No Historical information available for 5R29GM055223-03
Similar Projects
No Similar Projects information available for 5R29GM055223-03